Pheochromocytoma Metastasis to the central nervous system: A case report and systematic review

Justyna Fercho^1,2,3*Oskar Gerald Chasles⁴Jakub Chamier-Gliszczyński⁴Dominik Płaza⁴Bogdan Jabłoński⁴Klaudia Kokot⁴Maciej Mielczarek⁵Małgorzata Małłek-Grabowska^6,7Jacek Szypenbejl²Adrian Szkudlarek¹Tomasz Szmuda⁸Mariusz Sieminski²Jacek Furtak¹

• ¹Neurosurgery Department, 10th Military Research Hospital and PolyClinic SPZOZ, Bydgoszcz, Poland
• ²Department of Emergency Medicine, Medical University of Gdansk, Gdańsk, Poland
• ³Neurosurgery Department, Swissmed Luxmed Hospital in Gdańsk, Gdańsk, Poland
• ⁴Scientific Circle of Neurotraumatology, Medical University of Gdansk, Gdańsk, Poland
• ⁵Neurosurgery Department, Stanisław Staszic Specialist Hospital, Piła, Poland
• ⁶Department of Anesthesiology and Intensive Therapy, 10th Military Research Hospital and PolyClinic SPZOZ, Bydgoszcz, Poland
• ⁷Faculty of Medicine, Politechnika Bydgoska im Jana i Jedrzeja Sniadeckich, Bydgoszcz, Poland
• ⁸Neurosurgery Department, Medical University of Gdansk, Gdańsk, Poland

Background: Pheochromocytoma (PCC) is a rare neuroendocrine tumor, with 10–15% of cases showing malignant behavior defined by metastatic spread, including exceptionally rare central nervous system (CNS) involvement. Brain metastases present unique diagnostic and therapeutic challenges due to their potential to impair neurological function. This study reports a case of malignant PCC (mPCC) with CNS metastases and a systematic review to clarify the clinical patterns, management strategies, and prognostic factors. Methods: We describe the surgically managed case of a 41-year-old man with right frontoparietal brain metastasis. A systematic review, adhering to the PRISMA 2020 guidelines, searched PubMed, Scopus, and Web of Science for peer-reviewed studies on mPCC with brain or spinal metastases confirmed by radiology or histopathology. Data on demographics, symptoms, imaging, treatments, and outcomes were extracted and descriptively analyzed using Python-generated graphics. Results: This review identified 18 cranial (1948–2022) and 60 spinal (1977–2024) metastasis cases from 53 studies. Cranial metastases were present at a mean age of 46.6 years (SD 14.1), commonly with headaches (44.4%) and neurological deficits, such as weakness, presented in our case, with 72.2% surgically treated. Spinal metastases occurred at a mean age of 44.5 years (SD, 16.0), often with hypertension (51.7%) or pain, with a mean of 1.7 lesions (SD 1.5). The patient achieved short-term symptom relief post-resection, but incomplete follow-up (33.3% cranial) and reporting gaps (63.3% spinal laterality) limited the prognostic insights. MRI and PET improved the diagnostic accuracy over historical non-contrast CT use (41.7% spinal cases). Interpretation: CNS mPCC metastases are exceedingly rare with distinct neurological (cranial) and structural (spinal) presentations. Advanced imaging, particularly magnetic resonance imaging (MRI) and positron emission tomography (PET), is critical for accurate diagnosis and surgical planning. Sparse data underscores the need for registries and prospective studies to standardize care and improve outcomes.